QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NASDAQ:ILMN

Illumina - ILMN Stock Forecast, Price & News

$190.79
-3.02 (-1.56%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$183.65
$194.22
50-Day Range
$184.12
$227.44
52-Week Range
$173.45
$428.00
Volume
2.78 million shs
Average Volume
1.29 million shs
Market Capitalization
$29.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$262.60

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.31 Rating Score
Upside/​Downside
39.2% Upside
$265.60 Price Target
Short Interest
Healthy
2.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.54mentions of Illumina in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$107,800 Sold Last Quarter
Proj. Earnings Growth
49.46%
From $2.79 to $4.17 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

60th out of 1,093 stocks

Analytical Instruments Industry

5th out of 29 stocks

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

What’s Going On With Illumina (ILMN)?
Illumina (ILMN) Stock Moves -1.61%: What You Should Know
Illumina to Host Upcoming Investor Day
Form 8-K ILLUMINA, INC. For: Sep 06 - StreetInsider.com
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
8/11/2022
Today
9/30/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$265.60
High Stock Price Forecast
$492.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
+37.6%
Consensus Rating
Hold
Rating Score (0-4)
2.31
Research Coverage
13 Analysts

Profitability

Net Income
$762 million
Pretax Margin
0.23%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.12 per share
Book Value
$68.71 per share

Miscellaneous

Free Float
156,896,000
Market Cap
$29.97 billion
Optionable
Optionable
Beta
1.16

Social Links


Key Executives

  • Mr. Francis A. deSouzaMr. Francis A. deSouza (Age 51)
    CEO & Director
  • Dr. Alexander Aravanis M.D.Dr. Alexander Aravanis M.D. (Age 45)
    Ph.D., CTO & Head of Research and Product Devel.
    Comp: $1.05M
  • Mr. Charles E. DadswellMr. Charles E. Dadswell (Age 63)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Susan H. TousiMs. Susan H. Tousi (Age 53)
    Chief Commercial Officer
    Comp: $1.04M
  • Stephanie Campos
    Pres
  • Dr. Joydeep Goswami M.B.A. (Age 51)
    Ph.D., Chief Strategy & Corp. Devel. Officer and Interim CFO
  • Mr. Kevin Carl Pegels
    Chief of Global Operations
  • Mr. Jose A. Torres Jr. (Age 47)
    Chief Accounting Officer & VP
  • Ms. Carissa Rollins
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    VP of Investor Relations













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2022?

13 analysts have issued 12-month price targets for Illumina's shares. Their ILMN share price forecasts range from $175.00 to $492.00. On average, they anticipate the company's share price to reach $265.60 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2022?

Illumina's stock was trading at $380.44 at the beginning of the year. Since then, ILMN shares have decreased by 49.3% and is now trading at $192.96.
View the best growth stocks for 2022 here
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, August, 11th. The life sciences company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.63 by $0.06. The life sciences company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.22 billion. Illumina had a negative net margin of 0.43% and a positive trailing twelve-month return on equity of 5.61%. Illumina's revenue was up 3.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.87 earnings per share.
Read the conference call transcript
.

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2022 earnings guidance on Thursday, September, 8th. The company provided EPS guidance of $2.75-$2.90 for the period, compared to the consensus estimate of $4.12. The company issued revenue guidance of $4.71 billion-$4.75 billion, compared to the consensus revenue estimate of $5.19 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $192.96.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $30.31 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Illumina have?

The company employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.